Abstract: There is provided an apparatus comprising a receptacle to receive a sample. A sample dispenser dispenses the sample into the receptacle and an image capture device captures an image of the sample in the receptacle. Processing circuitry processes the image to determine whether the receptacle contains zero cells, exactly one cell, or more than one cell. In response to the processor determining that the receptacle contains zero cells, the processing circuitry causes the sample dispenser to dispense a further sample into the receptacle.

Abstract: This disclosure relates to a device for separating regenerative and/or adult stem cells from a fatty tissue taken from a biological structure. In one embodiment, the device includes a container for holding a substance mixture, the substance mixture including the fatty tissue and the regenerative and/or adult stem cells, and the container including at least two chambers separated from each other by at least one membrane. The device additionally includes a substance mixture feeding facility configured to introduce the substance mixture into the container, a rinsing agent feeding facility configured to introduce a fluid into the container, a stem cell removal facility configured to remove separated stem cells from the container, a rinsing agent removal facility configured to remove a substance mixture from the container that has been at least partially depleted of regenerative and/or adult stem cells, and a specifically permeable membrane.

Abstract: A method of culturing Antrodia cinnamomea with high Triterpenoids includes mixing a malt extract, glucose, peptone, agar, and a mushroom's extract with distilled water to obtain a culture medium; providing the culture medium to a high-pressure sterilization machine for sterilization to obtain a sterilized culture medium; providing the sterilized culture medium to an incubator in a disinfection environment to obtain a solidified culture medium after a predetermined time; transplanting Antrodia cinnamomeas strains to the solidified culture medium at separated positions; and exposing the solidified culture medium under a beam.

Abstract: A method of making a flowable, dried agglomerated nutrient medium is provided. The method comprises introducing a nutrient component comprising a powdered nutrient, and an agglomeration liquid, into an agglomerator comprising a flow-through-type agglomeration chamber, wet-massing the nutrient component with the agglomeration liquid in the agglomeration chamber for a predetermined period of time to form agglomerated nutrient medium particles, and exposing the agglomerated nutrient medium particles to drying conditions for a period of time to form the dried, agglomerated nutrient medium. The nutrient component facilitates the growth of a microorganism. Compositions, articles, and kits comprising the flowable, dried agglomerated nutrient medium are also provided.

Abstract: Cell culture media, concentrated media and feeds, methods of manufacturing cell culture media and feeds, and methods of culturing cells are provided. One or more small peptides, including dipeptides are added to the cell culture media to provide improved stability and improved conditions for culturing cells.

Abstract: The present invention relates to dry cell culture media comprising amino acid components of certain particle size. Some dry powder cell culture media show poor dissolving properties and result in turbid solutions when they are dissolved in aqueous solutions. Using amino acid components of certain particle sizes significantly reduces that problem.

Abstract: In one example, the present invention refers to a method of making or producing a self-supporting cellular construct having a continuous channel within its central cavity, comprising the steps of providing a mould with a central opening, wherein the mould encloses a volume around the central opening (hole) capable of housing a plurality of cells. Each of the plurality of self-supporting cellular constructs, having a central opening in a series adjacent to one another such, is placed so that the central opening of each of the self-supporting cellular constructs having a central opening is aligned to one another to thereby form, for example, a continuous channel within its central cavity.

Abstract: A method for micro-tissue encapsulation of cells includes coating a tissue scaffold stamp with an extracellular matrix compound; depositing the tissue scaffold stamp onto a thermoresponsive substrate; seeding the tissue scaffold stamp with a cell culture; incubating the cell culture on the tissue scaffold stamp at a temperature that is specified, wherein the cell culture forms a cell patch that is attached to the extracellular matrix compound; removing the thermoresponsive substrate by lowering the temperature; removing the tissue scaffold stamp from the cell patch to form a micro-tissue structure by dissolving the tissue scaffold stamp in a solvent; folding the micro-tissue structure by suspending the micro-tissue in the solvent to enable the cell patch to fold the micro-tissue structure; collecting the folded micro-tissue structure from the solvent; and administering the folded micro-tissue structure to an organism.

Abstract: The present invention relates to a cell culture support comprising a substrate and a polymeric blend layer bound to the substrate. The polymeric blend layer comprises at least one thermoresponsive polymer and at least one coupling agent. The coupling agent is a non-protein coupling agent that has functional thiol, ester, epoxy, or aldehyde groups. The cell culture support further includes cells supported by the polymeric blend layer, wherein the thermoresponsive polymer provides for temperature induced detachment of the cells and/or cell sheets.

Abstract: A fiber structure can be used as a cell scaffold material, which fiber structure includes a multifilament formed by bundling monofilaments having an average fiber diameter of 1 to 15 ?m, wherein each of the monofilaments satisfies Formula (1): (Y/X)×100>50 . . . (1) wherein, in Formula (1), X represents the number of monofilaments for which the average crossing angle is investigated, and Y represents the number of monofilaments having an average crossing angle of not more than 25° in X.

Abstract: A cell culture carrier includes a first substrate. The first substrate has a plurality of wells on an upper surface and includes a porous body. The porous body has pores with an average pore diameter of 0.05 ?m or more and 10 ?m or less, and has a porosity of 25% or more and 50% or less. The first substrate has a thickness from a lowermost portion of the well to a lower surface of the substrate of 50 ?m or more and 10 mm or less.

Abstract: The present disclosure is related to methods for forming a stem cell bank. The methods include obtaining a first stem cell from a multi-cell fertilized embryo, expanding the first stem cell into two or more descendant stem cells, and storing at least one of the descendant stem cells to form the stem cell bank. Also disclosed is a kit that can be used for making the stem cell bank during in vitro fertilization. If desired, the HLA serotype of the stem cells can be determined prior to storage.

Abstract: The present invention relates to a composition and method for assisted reproductive technology in mammals. In particular, the present invention provides compositions and methods for in vivo maturation of an immature cumulus oocyte complex (COC), thereby enhancing the embryology outcome.

Abstract: The present invention relates to methods of treating or ameliorating certain neurodegenerative disorders (namely, dysmyelinating and demyelinating disorders) in patients in need of such treatment or amelioration. The invention provides methods of treating or ameliorating a patient in need of such treatment and includes the administration to the patient of: (a) thyroid hormones or thyroid hormone analogues; (b) cell replacement therapies involving the use of homogenous Oligodendrocyte Precursor Cells derived from embryonic stem cells that have been treated with thyroid hormones or thyroid hormone analogues; (c) gene therapy to correct mutated genes in vivo; or (d) a combination of two or more of (a), (b) and (c). The invention also provides compositions and formulations of thyroid hormones and thyroid hormone analogues for use in treating or ameliorating such disorders.

Abstract: A method for expanding a population of ?? T-cells is provided in which isolated activated Peripheral Blood Mononuclear Cells (PBMCs) are cultured in a medium comprising transforming growth factor beta (TGF-?) under conditions in which the production of effector ?? T-cells having therapeutic activity against malignant disease is favored. The use of TGF-? in the production of effector cells in particular V?9V?2 T-cells is also described and claimed.

Abstract: An aluminoborate glass composition, including B2O3, Al2O3, P2O5, Na2O, and CaO, as defined herein. Also disclosed are bioactive compositions including the disclosed aluminoborate glass composition, a suitable fluid, and at least one live cell. Also disclosed is method of limiting the amount of boron released into an aqueous solution from a disclosed aluminoborate-containing glass composition as defined herein. Also disclosed is a method of proliferating cells on a bioactive substrate as defined herein.

Abstract: A bioactive glass-ceramic composition as defined herein. Also disclosed are methods of making and using the disclosed compositions.

Abstract: Provided are methods of isolating pericyte progenitor cells from pluripotent stem cells such as embryonic stem cells and induced pluripotent stem cells, by isolating CD105+, CD73+ and/or CD105+/CD73+ cells from embryoid bodies and optionally by enriching the cells with CD31? cells. Also provided are methods of isolating endothelial cells and co-derivation of pericyte and endothelial cells progenitor cells from embryoid bodies, and methods of differentiating same for various therapeutic applications. In addition, the invention provides an isolated pericyte progenitor cell having an expression marker signature of CD105+/CD73+CD31?/alpha SMA?/CD133?/Flk-1?.

Abstract: The invention relates to improved culture methods for expanding epithelial stem cells and obtaining organoids, to culture media involved in said methods, and to uses of said organoids.

Abstract: The disclosure relates to a method of reprogramming one or more somatic cells, e.g., partially differentiated or fully/terminally differentiated somatic cells, to a less differentiated state, e.g., a pluripotent or multipotent state. In further embodiments the invention also relates to reprogrammed somatic cells produced by methods of the invention, to uses of said cells, and to methods for identifying agents useful for reprogramming somatic cells.

Abstract: The present invention relates to a novel porcine pestivirus, to proteins of the virus and to vaccines based upon the virus and proteins thereof. The invention also relates to DNA fragments comprising a gene of the virus and to DNA vaccines based upon genes of the virus. Furthermore the invention relates to antibodies that are reactive with the novel virus and to diagnostic tests for the detection of the virus or antibodies against the virus.

Abstract: The disclosure relates to acyl-ACP reductase (AAR) enzyme variants that result in improved fatty aldehyde and fatty alcohol production when expressed in recombinant host cells. The disclosure further relates to methods of making and using such AAR variants for the production of fatty alcohol compositions having particular characteristics.

Abstract: The present invention pertains to an isolated P450 enzyme comprising or consisting of an amino acid sequence at least 80% identical to SEQ ID NO: 1, wherein said sequence comprises a threonine at position corresponding to position 225 and/or an aspartic acid mutation at position corresponding to position 289. The invention also concerns an isolated nucleic acid comprising a sequence encoding said enzyme, a vector comprising said nucleic acid, and a host cell containing said nucleic acid or said vector. Methods for preparing said enzyme and methods for producing steroid hormone precursors using the enzyme or the host cells featured in the invention are also provided.

Abstract: The present invention relates to cell lines that are genetically modified to overexpress a ?-galactoside ?-2,3-sialyltransferase 1 (ST3Gal1), preferably human ST3Gal1, which can be used for the production of recombinant glycoproteins having highly or fully sialylated O-linked GalNAc glycans (GalNAc O-glycans), preferably core 1 GalNAc O-glycans, as well as to respective recombinant glycoproteins. Further, the present invention relates to respective methods of expressing recombinant glycoproteins, methods of increasing the degree of sialylation of recombinant glycoproteins, and methods of decreasing the micro-heterogeneity of GalNAc O-glycans. Finally, the present invention relates to respective uses of the above cell lines for the production of recombinant glycoproteins, for increasing the degree of sialylation of recombinant glycoproteins, and for decreasing the micro-heterogeneity of O-linked GalNAc glycans of recombinant glycoproteins.

Abstract: The present invention relates enzyme composition comprising a cellulolytic preparation and an acetylxylan esterase (AXE); and the used of cellulolytic enzyme compositions for hydrolyzing acetylated cellulosic material. Finally the invention also relates to processes of producing fermentation products from acetylated cellulosic materials using a cellulolytic enzyme composition of the invention.

Abstract: The present invention relates to a method for controlling a glycosylation pattern of a recombinant glycoprotein, comprising culturing a cell comprising polynucleotide encoding a recombinant glycoprotein in a culture medium comprising insulin.

Abstract: The present invention relates to glucoamylase variants having improved thermostability. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

Abstract: The present invention relates to isolated polypeptides having protease activity and isolated nucleic acid sequences encoding the proteases. The invention also relates to nucleic acid constructs, vectors, and host cells, including plant and animal cells, comprising the nucleic acid sequences, as well as methods for producing and using the proteases, in particular the use of the proteases in animal feed.

Abstract: Chromatographic processes and systems for purifying a botulinum toxin from an APF fermentation medium.

Abstract: The present invention relates to protease variants and methods for obtaining protease variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

Abstract: A process for refolding recombinant chymotrypsin produced from prokaryote host cells is described. In particular, the present invention provides a process for refolding recombinant chymotrypsin produced from E. coli is described.

Abstract: Microfluidic devices and methods for the encapsulation of particles within liquid droplets are disclosed. The new methods and devices form 1-100 picoliter-size monodisperse droplets containing the particles, such as single cells, encapsulated in individual liquid droplets. The particles can be encapsulated in droplets of a fluid by passing a fluid containing the particles through a high aspect-ratio microchannel to order the particles in the fluid, followed by forming the fluid into droplets. The resulting fraction of the liquid droplets with a single particle (e.g., a cell) is higher than the corresponding fraction of single-particle liquid droplets predicted by Poisson statistics.

Abstract: The presently disclosed subject matter provides methods and kits for purifying nucleic acids from blood plasma using a functionalized solid phase comprising a silica or polymer backbone and non-chaotropic and ethanol-free buffers.

Abstract: A three-layer complex including at least one magnetic compound, at least one inorganic silicate and at least one compound having an affinity for the at least one magnetic compound and/or the at least one inorganic silicate. The three-layer complex, and associated methods, may be applicable in the field of in vitro diagnostics.

Abstract: In accordance with one embodiment of the present invention, there is disclosed an apparatus for nucleic acid extraction and an operation method thereof. The apparatus for nucleic acid extraction includes: a first rack having a plurality of sample tube receivers arranged in a circle; a second rack having a plurality of elution tube receivers arranged in a circle on an outer side thereof and a washing solution receiver positioned at the center thereof, a part of the washing solution receiver extending outwards to have projections formed in alternation with a plurality of the elution tube receivers; a main body having the first and second racks arranged to position the first rack on the top of the second rack; a rotational driver for separately rotating the first and second racks; a dispenser for separately dispensing a washing solution and an eluting solution into sample tubes; and a pressurizer for maintaining the inside of the sample tubes under raised pressure.

Abstract: The invention provides methods for isolating RNA from whole urine and urine fractions for the diagnosis of prostate cancer and/or benign prostate hyperplasia. An exemplary method for diagnosing prostate cancer in an individual, said method comprises: (a) determining the amount of RNA encoding one or more diagnostic genes in the soluble urine fraction of a urine sample obtained from said individual; (b) comparing the amount of said RNA to a reference value for said one or more diagnostic genes, wherein said reference value is derived from the amount of RNA encoding said one or more diagnostic genes in one or more individuals that do not have prostate cancer; and (c) diagnosing said individual as having prostate cancer when the amount of said RNA is greater than said reference value.

Abstract: The present invention inter alia pertains to a method for generating or selecting a eukaryotic host cell expressing a desired level of a polypeptide of interest, comprising: a) providing a plurality of eukaryotic host cells comprising a heterologous nucleic acid comprising at least one cassette (Cas-POI) comprising at least a first polynucleotide (Pn-POI) encoding the polypeptide of interest, at least one stop codon downstream of the first polynucleotide, and a second polynucleotide downstream of the stop codon encoding an immunoglobulin transmembrane anchor or a functional variant thereof; b) cultivating the eukaryotic host cells to allow expression of the polypeptide of interest such that at least a portion of the polypeptide of interest is expressed as a fusion polypeptide comprising the immunoglobulin transmembrane anchor or a functional variant thereof, wherein said fusion polypeptide is being displayed on the surface of said host cell; c) selecting at least one eukaryotic host cell based upon the pre

Abstract: The present disclosure provides compositions, methods, systems, and devices for polynucleotide processing. Such polynucleotide processing may be useful for a variety of applications, including polynucleotide sequencing.

Abstract: The present disclosure relates to compositions, methods and kits for labeling an internal sequence of a target nucleic acid molecule with molecular barcodes. In some embodiments, the methods comprise intramolecular circulation of a labeled target nucleic acid molecule. Further provided methods for generating sequencing libraries comprising overlapping fragments covering the full length of a target nucleic acid molecule, sequencing the libraries using the methods disclosed herein, and methods of analyzing sequencing results therefrom.

Abstract: The present invention provides methods for creating an array of features on a surface based on content transferred from a plurality of beads to the surface. Nucleic acid content can be transferred using a method including the steps of (a) providing a surface having one or more primer oligonucleotides attached to the surface; (b) providing a pool of beads, wherein beads in the pool have a plurality of templates attached thereto, the plurality comprising multiple copies of a single nucleic acid template sequence; (c) arraying the beads onto the surface by hybridizing the templates to the primer oligonucleotides; and (d) extending the primers to produce copies of the templates attached to the surface.

Abstract: Described is a method for identifying a gene which mediates antibiotic sensitivity or resistance in a target bacterium, the method comprising the steps of: (a) generating a pool of mutant target bacteria by transposon mutagenesis with an activating transposon (TnA), wherein the TnA comprises an outward-facing promoter (TnAP) capable of increasing transcription of a gene at or near its insertion site in the DNA of said target cells; (b) generating a control microdroplet library by encapsulating individual members of the pool of step (a) in microdroplets, the microdroplets comprising a volume of aqueous growth media suspended in an immiscible carrier liquid, each microdroplet comprising a single mutant target cell; (c)generating a test microdroplet library by encapsulating individual members of the pool of step (a) in microdroplets, the microdroplets comprising a volume of aqueous growth media containing the antibiotic and suspended in an immiscible carrier liquid, each microdroplet comprising a single mutant t

Abstract: The present disclosure relates to methods for determining recombination diversity at a genomic locus of interest. The method includes fragmenting nucleic acids isolated from immune cells, ligating adaptors to the fragmented or amplified nucleic acids, and selectively amplifying nucleic acids containing a recombined junction at the genomic locus of interest. Selective amplification is achieved by using a first primer that hybridizes to an adaptor sequence and a second primer that hybridizes at a constant region downstream of the recombined junction. The selectively amplified nucleic acids may be sequences and analyzed to determine recombination diversity at the genomic locus.

Abstract: A method of ligating DNA molecules, wherein the DNA molecules are in a hybrid with an RNA molecule, including the steps of providing DNA molecules that are in a RNA:DNA hybrid with an RNA molecule, and ligating the DNA molecules to each other with a double strand specific ligase

Abstract: Provided is an improved design of shRNA based on structural mimics of miR-451 precursors. These miR-451 shRNA mimics are channeled through a novel small RNA biogenesis pathway, require AGO2 catalysis and are processed by Drosha but are independent of DICER processing. This miRNA pathway feeds active elements only into Agog because of its unique catalytic activity. These data demonstrate that this newly identified small RNA biogenesis pathway can be exploited in vivo to produce active molecules.

Abstract: The present invention provides methods and pharmaceutical compositions for treating human immunodeficiency virus type 1 (HIV-1) infections. In particular, the present invention relates to a method for treating HIV-1 infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of an inhibitor of SGT1 activity or expression.

Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.

Abstract: A novel class of pharmaceuticals which comprises a Locked Nucleic Acid (LNA) which can be used in antisense therapy. These novel oligonucleotides have improved antisense properties. The novel oligonucleotides are composed of at least one LNA selected from beta-D-thio/amino-LNA or alpha-L-oxy/thio/amino-LNA. The oligonucleotides comprising LNA may also include DNA and/or RNA nucleotides.

Abstract: The present invention relates to the fields of medicine and immunology. In particular, it relates to novel antisense oligonucleotides that may be used in the treatment, prevention and/or delay of Leber congenital amaurosis.

Abstract: The present invention relates to the prevention and the treatment of extracapillary glomerulonephritis such as rapidly progressive glomerulonephritis and collapsing glomerulonephritis.

Abstract: The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules capable of mediating RNA interference (RNAi) against target nucleic acid sequences. The small nucleic acid molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.